Analysts Offer Insights on Healthcare Companies: Adicet Bio (NASDAQ: ACET) and Durect (NASDAQ: DRRX)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adicet Bio (ACETResearch Report) and Durect (DRRXResearch Report) with bullish sentiments.

Durect (DRRX)

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Durect on September 23 and set a price target of $5.00. The company’s shares closed last Friday at $1.86.

According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 16.2% and a 47.6% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.

Durect has an analyst consensus of Strong Buy, with a price target consensus of $6.00, implying a 233.3% upside from current levels. In a report issued on September 23, Oppenheimer also reiterated a Buy rating on the stock with a $7.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.